62.25 +0.66 (1.07%)
After hours: 5:00PM EDT
|Bid||61.01 x 1000|
|Ask||62.23 x 27000|
|Day's Range||61.28 - 62.29|
|52 Week Range||49.96 - 70.05|
|PE Ratio (TTM)||273.73|
|Forward Dividend & Yield||1.60 (2.64%)|
|1y Target Est||N/A|
Bristol-Myers Squibb Company today announced that the European Medicines Agency has validated the Company’s type II variation application for Empliciti in combination with pomalidomide and low-dose dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor , and have demonstrated disease progression ...
The Board of Directors of Bristol-Myers Squibb Company today declared a quarterly dividend of forty cents per share on the $.10 par value Common Stock of the corporation.
Efficacy endpoints including ≥75% and 90% reduction in the Psoriasis Area and Severity Index were achieved following 12 weeks of treatment with ≥3 mg daily of BM
Bristol-Myers Squibb Company (BMY) will take part in the Morgan Stanley 2018 Global Health Care Conference on Thursday, September 13, 2018, in New York. Giovanni Caforio, M.D., chairman and chief executive officer will make formal remarks about the company and answer questions at 11:10 a.m. EDT. Investors and the general public are invited to listen to a live webcast of the session at http://investor.bms.com.
Bristol-Myers Squibb Company will announce results for the third quarter of 2018 on Thursday, October 25, 2018. During a conference call at 10:30 a.m. EDT on October 25, company executives will review financial information and will address inquiries from investors and analysts.
Today, for the fifth year in a row, Bristol-Myers Squibb Company (BMY) is launching Coast 2 Coast 4 Cancer, a nearly month-long cross-country bike ride to raise money for cancer research. From September 5-25, 109 company employees will ride a total of nearly 3,000 miles from Cannon Beach, OR, to Long Branch, NJ with the goal of raising $1 million for the V Foundation for Cancer Research. Funds raised will be matched dollar for dollar by Bristol-Myers Squibb Company, up to a $500,000 maximum donation.
Application based on results from Phase 2 CA180-372 study
Bristol-Myers Squibb Company today announced that Christopher Boerner, Ph.D., has been appointed executive vice president and chief commercial officer, effective immediately.
Application based on results from Phase 2 ELOQUENT-3 study
#FDA approves $BMY therapy for certain previously treated patients with advanced small cell #LungCancer
NEW YORK, Aug. 08, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cytosorbents ...
NEW YORK, NY / ACCESSWIRE / July 31, 2018 / U.S. markets continued to drop on Monday, as tech sector close in the red weighed by majority of the FAANG (Facebook, Apple, Amazon, Netflix and Google parent ...
Opdivo is the first and only PD-1 agent with an approved adjuvant therapy indication in the European Union
NEW YORK-- -- Increases Second Quarter Revenues 11% to $5.7 Billion Posts Second Quarter GAAP EPS of $0.23 and Non-GAAP EPS of $1.01 Achieves Significant Regulatory Milestones in Oncology Presents Important New Data on Immuno-Oncology Portfolio at ASCO Updates 2018 GAAP and Non-GAAP EPS Guidance Bristol-Myers Squibb Company today reported results for the second quarter of 2018, which were highlighted ...
NEW YORK, NY / ACCESSWIRE / July 25, 2018 / U.S. markets finished moderately higher on Tuesday, fueled by strong corporate earnings as Google quarterly results topped expectations. The Dow Jones Industrial ...
Bristol-Myers Squibb Company (BMY) and Tsinghua University, have entered into a collaboration to discover therapeutic agents against novel targets for autoimmune diseases and cancers. The collaboration brings together Bristol-Myers Squibb and Tsinghua University’s respective scientific expertise and capabilities with a focus on validating new targets and generating early drug candidates for clinical development. Under the collaboration, The Innovation Center for Immune Therapy of Tsinghua University will conduct research on projects and Bristol-Myers Squibb will have an option to exclusively license therapeutic agents discovered by Tsinghua University.
Bristol-Myers Squibb Company (BMY) today announced that Murdo Gordon, executive vice president and chief commercial officer, is leaving the company, effective August 3, 2018, to pursue another opportunity. "On behalf of the company, I want to thank Murdo for his leadership and the important contributions he’s made in his many years with Bristol-Myers Squibb,” said Giovanni Caforio, chairman and chief executive officer, Bristol-Myers Squibb.
Bristol-Myers Squibb Company and Gritstone Oncology today announced that the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Gritstone’s personalized neoantigen immunotherapy, GRANITE-001, which comprises sequential delivery of neoantigens to patients within an adenovirus-based vector and a self-replicating RNA-based vector , in combination with ...
Bristol-Myers Squibb’s Opdivo® + Low-Dose Yervoy® is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following T
Only Immuno-Oncology Combination Therapy Approved by Health Canada as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
LONDON, UK / ACCESSWIRE / July 9, 2018 / If you want access to our free research report on Bristol-Myers Squibb Co. (NYSE: BMY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BMY as the Company's latest news hit the wire. On July 05, 2018, the Company announced that the European Commission (EC) has approved the indication for Sprycel (dasatinib) to treat children and adolescents aged 1 year to 18 years with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP), and to include a powder for oral suspension formulation.
Approval includes the first powder for oral suspension formulation of a tyrosine kinase inhibitor developed for administration in pediatric patients
Bristol-Myers Squibb Company today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended expanded approval of the current indications for Opdivo to include the adjuvant treatment of adult patients with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.
LONDON, UK / ACCESSWIRE / June 26, 2018 / If you want access to our free research report on Bristol-Myers Squibb Co. (NYSE: BMY), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BMY as the Company's latest news hit the wire. On June 22, 2018, the Company announced that the US Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in combination with low-dose Yervoy (ipilimumab) for the treatment of first-line advanced non-small cell lung cancer (NSCLC) in patients with tumor mutational burden (TMB) ≥10 mutations per megabase (mut/Mb).
Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration has accepted its supplemental Biologics License Application for Opdivo plus low-dose Yervoy for the treatment of first-line advanced non-small cell lung cancer in patients with tumor mutational burden ≥10 mutations per megabase .